期刊文献+

雷替曲塞治疗难治复发白血病临床观察 被引量:1

暂未订购
导出
摘要 白血病是血液系统常见的恶性肿瘤。在我国35岁以下的恶性肿瘤患者中,白血病是导致死亡的主要原因。目前,白血病的治疗已经取得了很大进展,通过化疗、造血干细胞移植、分子生物学治疗等先进手段,已大大延长了白血病患者的生存期,但仍存在复发、难治的问题。多年来,关于难治及复发白血病的治疗问题一直是血液系统恶性肿瘤领域里研究的难点及热点。到目前为止,难治及复发白血病尚无理想的治疗方案。并且缓解率低。难治及复发白血病对多种化疗药物出现耐药现象,其治疗是目前临床上的难题,用普通化疗方案缓解率低,生存期短,近年来不断更新化疗方案,但疗效亦欠佳。本研究应用雷替曲塞治疗难治复发白血病取得一定的疗效,并且对其安全性进行了评估。
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2013年第4期446-447,共2页 Journal of Chongqing Medical University
基金 黑龙江省留学人员归国基金资助项目(编号:LC08C24)
  • 相关文献

参考文献15

  • 1刘小莲,刘志,朱万寿,黄世俭,李胜华.IEA方案治疗难治性急性淋巴细胞白血病疗效观察[J].中国实用医药,2011,6(11):41-42. 被引量:7
  • 2唐晓文,魏孝艾,孙爱宁,陈峰,胡晓慧,颜灵芝,韩悦,顾斌,沈文红,吴德沛.地西他滨联合抗CD33单抗治疗难治性急性髓细胞性白血病(附2例报告)[J].苏州大学学报(医学版),2011,31(2):272-275. 被引量:5
  • 3孟凡义.成人高危急性髓系白血病的诊治策略[J].实用医学杂志,2008,24(12):2017-2018. 被引量:4
  • 4Chawla B,Kanate A S,Osman S,et al.Clofarabine in combination with Cyclophosphamide for treatment of relapsed/refractory acute leukemia in adult patients[J].Blood, 2010,116 (12) : 4367-4372.
  • 5Blum W,Klisovic R B,Becker H,et al.Dose escalation of lenalido- mide in relapsed or refractory acute leukemias[J].J Clini Oncol,2010, 28 (33) : 4919-4925.
  • 6Wei G Q, Ni W M, Chiao J W,et al.A meta-analysis of CAG (cy- tarabine,aclarubicin, G-CSF) regimen for the treatment of 1 029 pa- tients with acute myeloid leukemia and myelodysplastic syndrome[J].J Hematol Oncol, 2011,4(4) : 46.
  • 7Filicko-O'Hara J,Mookerjee B,Alpdogan O,et al.Phase lI study of Bortezomib, Mitoxantrone and Etoposide in relapsed/refractory acute leukemias[J].Blood, 2010,116 ( 6 ) : 2192.
  • 8王谦,仇惠英,吴德沛,孙爱宁,金正明,苗瞄,唐晓文,傅铮铮,韩悦,何广胜.抗CD33单抗联合化疗药物治疗复发或难治性急性髓系白血病的疗效观察[J].苏州大学学报(医学版),2011,31(2):317-320. 被引量:6
  • 9Takemura Y,Gibson W,Kimbell R,et al.Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resis- tant,to this drug[J].J Cancer Res Clin Oncol, 1996,122(2) : 109 -117.
  • 10Takemura Y,Kobayashi H,Miyachi H.Raltitrexed,a novel folate- based thymidylate synthase inhibitor,for the treatment of acute leukemia:is this drug active,against,acute,myelogenous,leukemia[J]. Int, J, Hematol, 2000,72 ( 1 ) : 112-114.

二级参考文献27

  • 1赵桂兰.去甲氧柔红霉素治疗难治性急性髓系白血病的疗效分析[J].内蒙古医学院学报,2005,27(5):36-37. 被引量:4
  • 2孙爱宁,吴德沛,唐晓文,傅铮铮,马骁,仇惠英,金正明,苗瞄,沈益明,常伟荣,朱子玲.异基因造血干细胞移植治疗恶性血液病的临床研究[J].苏州大学学报(医学版),2004,24(5):675-677. 被引量:2
  • 3顾龙君,陈静,曹兰芳,赵惠君,谢晓恬.用去甲氧柔红霉素联合方案治疗难治性儿童急性淋巴细胞白血病[J].中华血液学杂志,1995,16(7):368-368. 被引量:2
  • 4张之南.血液病诊断及疗效标准.第3版.天津科学技术出版社,2008,152-1911.
  • 5Seipelt G,Hofmann W K.Comparison of toxicity and outcome in patients with acute myeloid leukem ia treated with high-dose cytosine arabino side conso lidation after induction with a regimen containing idarubicin o rdauno rubicin.A nn Hemato l,1998,76(3):145.
  • 6Alvarado Y,Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg,idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia[J]. Cancer Chemother Pharmacol,2003,51 (1): 87 - 90.
  • 7Chevallier P, Delaunay J,Turlure P, et al. Long-term dis- ease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia [ J ]. J Clin Oncol,2008,26(32) :5192-5197.
  • 8Lowenberg B, Beck J, Graux C, et al. Gemtuzumab ozo- gamicin as postremission treatment in AML at 60 years of age or more: resuhs of a multicenter phase 3 study [ J ]. Blood,2010,115 (13) :2586 - 2591.
  • 9Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gem- tuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo my- eloablative allogeneic stem cell transplantation [ J ]. Blood, 2003.102 ( 5 ) : 1578 - 1582.
  • 10Cohen AD, Luger SM, Sickles C, et al. Gemtuzumab ozogamicin(Mylotarg) monotherapy for relapsed AML after hematopoitetic stem cell transplant;efficacy and incidence of hepatic veno-oclusive disease[ J ]. Bone Marrow Trans- plant,2002,30( 1 ) :23 - 28.

共引文献15

同被引文献24

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部